Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015538

SCHEMBL1015538

SCHEMBL1015538

O=Cc1c(Br)ccc(C(F)(F)F)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 3/20 0.39
▸ ERN1 O75460 2/20 0.36
▸ NOTUM Q6P988 1/20 0.33
▸ MAPT P10636 3/20 0.32
▸ HTT P42858 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ XBP1 P17861 1/20 0.30
▸ CTSS P25774 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952070 0.85 KIF11 (0.39) KIF11ERN1NOTUMMAPTMEN1
SCHEMBL9340547 0.80 CYP2C9 (0.46) KIF11ERN1CYP2D6CYP2C9CTSS
SCHEMBL671603 0.79 ERN1 (0.35) KIF11ERN1NOTUMMAPTHTT
SCHEMBL29504018 0.79 ERN1 (0.42) ERN1MEN1KMT2A
SCHEMBL1418396 0.79 ERN1 (0.42) ERN1MEN1KMT2A
SCHEMBL8401425 0.78 KIF11 (0.36) KIF11ERN1NOTUMMAPTMEN1
SCHEMBL6723791 0.77 KIF11 (0.39) KIF11CYP2D6CYP2C9CTSSNFKB1
SCHEMBL31165603 0.77 KIF11 (0.35) KIF11ERN1NOTUMLMNACA1
SCHEMBL6723976 0.77 ALDH1A1 (0.43) KIF11NOTUMMEN1KMT2ACYP2D6
SCHEMBL8401545 0.76 KIF11 (0.34) KIF11ERN1NOTUMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12256736-B2 Pyridazine compound and herbicide NIPPON SODA CO., LTD. (JP) 2025-03-25 — — US disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
CN-116867373-A Herbicidal composition 日本曹达株式会社 2023-10-10 — — CN disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 — — US disclosed
WO-2022202642-A1 HERBICIDAL COMPOSITION 日本曹達株式会社 2022-09-29 — — WO disclosed
US-20220287305-A1 PYRIDAZINE COMPOUND AND HERBICIDE NIPPON SODA CO., LTD. (JP) 2022-09-15 — — US disclosed
EP-4036092-A1 PYRIDAZINE COMPOUND AND HERBICIDE Nippon Soda Co., Ltd. (JP) 2022-08-03 — — EP disclosed
CN-108699032-B Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders 默克专利有限公司 2022-07-22 — — CN disclosed
EP-3145918-A1 5-(HETERO)ARYL-PYRIDAZINONES AND THEIR USE AS HERBICIDES Bayer CropScience Aktiengesellschaft (DE) 2017-03-29 — — EP disclosed
EP-3145917-A1 5-(HETERO)ARYL-PYRIDAZINONES AND THEIR USE AS HERBICIDES Bayer CropScience Aktiengesellschaft (DE) 2017-03-29 — — EP disclosed
WO-2015177108-A1 5-(HETERO)ARYL-PYRIDAZINONES AND THEIR USE AS HERBICIDES BAYER CROPSCIENCE AG (DE) 2015-11-26 — — WO disclosed
WO-2015177109-A1 5-(HETERO)ARYL-PYRIDAZINONES AND THEIR USE AS HERBICIDES BAYER CROPSCIENCE AG (DE) 2015-11-26 — — WO disclosed
WO-2015177109-A1 5-(HETERO)ARYL-PYRIDAZINONES AND THEIR USE AS HERBICIDES BAYER CROPSCIENCE AG (DE) 2015-11-26 — — WO disclosed
EP-2271649-A1 BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF Wyeth LLC (US) 2011-01-12 — — EP disclosed
US-20100029657-A1 Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof WYETH (US) 2010-02-04 — — US disclosed
WO-2009108838-A1 BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF WYETH (US) 2009-09-03 — — WO disclosed
US-6677479-B2 REACTING A HALOGENATED BENZENE COMPOUND WITH ALDEHYDE; SOLVENT EXTRACTION; PURIFICATION CLARIANT FINANCE LBVI LIMITED (VG) 2004-01-13 — — US disclosed
US-20030092930-A1 Substituted fluoroaromatics, process for preparing them and their use CLARIANT GMBH 2003-05-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KIF11 4094/4885ERN1 659/4885NOTUM 4516/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KIF11 4094/4885ERN1 659/4885NOTUM 4516/4885
US-12256736-B2 Pyridazine compound and herbicide HCN1, CNPY2, MTX2 KIF11 2134/4885ERN1 3007/4885NOTUM 591/4885
US-20220287305-A1 PYRIDAZINE COMPOUND AND HERBICIDE HCN1, CNPY2, MTX2 KIF11 2134/4885ERN1 3007/4885NOTUM 591/4885
US-20100029657-A1 Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof BRAF, RAF1, ARAF KIF11 1722/4885ERN1 477/4885NOTUM 3956/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KIF11 4094/4885ERN1 659/4885NOTUM 4516/4885
US-20030092930-A1 Substituted fluoroaromatics, process for preparing them and their use CYP2F1, CYP1A1, CYP4X1 KIF11 2044/4885ERN1 3050/4885NOTUM 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.